Literature DB >> 30136609

Inhibition of the extrinsic or intrinsic coagulation pathway during pneumonia-derived sepsis.

Ingrid Stroo1,2, Chao Ding1,3, Andreja Novak1, Jack Yang1, Joris J T H Roelofs4, Joost C M Meijers5,6, Alexey S Revenko7, Cornelis van 't Veer1, Sacha Zeerleder2,8, Jeff R Crosby7, Tom van der Poll1,9.   

Abstract

Pneumonia is the most frequent cause of sepsis, and Klebsiella pneumoniae is a common pathogen in pneumonia and sepsis. Infection is associated with activation of the coagulation system. Coagulation can be activated by the extrinsic and intrinsic routes, mediated by factor VII (FVII) and factor XII (FXII), respectively. To determine the role of FVII and FXII in the host response during pneumonia-derived sepsis, mice were treated with specific antisense oligonucleotide (ASO) directed at FVII or FXII for 3 wk before infection with K. pneumoniae via the airways. FVII ASO treatment strongly inhibited hepatic FVII mRNA expression, reduced plasma FVII to ~25% of control, and selectively prolonged the prothrombin time. FXII ASO treatment strongly suppressed hepatic FXII mRNA expression, reduced plasma FXII to ~20% of control, and selectively prolonged the activated partial thromboplastin time. Lungs also expressed FVII mRNA, which was not altered by FVII ASO administration. Very low FXII mRNA levels were detected in lungs, which were not modified by FXII ASO treatment. FVII ASO attenuated systemic activation of coagulation but did not influence fibrin deposition in lung tissue. FVII ASO enhanced bacterial loads in lungs and mitigated sepsis-induced distant organ injury. FXII inhibition did not affect any of the host response parameters measured. These results suggest that partial inhibition of FVII, but not of FXII, modifies the host response to gram-negative pneumonia-derived sepsis.

Entities:  

Keywords:  coagulation; factor VII; factor XII; pneumonia; sepsis

Mesh:

Substances:

Year:  2018        PMID: 30136609     DOI: 10.1152/ajplung.00014.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  The future of sepsis research: time to think differently?

Authors:  Julie A Bastarache
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 6.011

2.  Prekallikrein inhibits innate immune signaling in the lung and impairs host defense during pneumosepsis in mice.

Authors:  Chao Ding; Brendon P Scicluna; Ingrid Stroo; Jack Yang; Joris Jth Roelofs; Onno J de Boer; Alex F de Vos; Peter Nürnberg; Alexey S Revenko; Jeff Crosby; Cornelis Van't Veer; Tom van der Poll
Journal:  J Pathol       Date:  2019-11-25       Impact factor: 7.996

3.  Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy.

Authors:  Federica Melazzini; Marta Colaneri; Federica Fumoso; Giulia Freddi; Marco Vincenzo Lenti; Teresa Chiara Pieri; Davide Piloni; Patrizia Noris; Carla Pieresca; Paola Stefania Preti; Mariaconcetta Russo; Angelo Corsico; Guido Tavazzi; Fausto Baldanti; Antonio Triarico; Francesco Mojoli; Raffaele Bruno; Antonio Di Sabatino
Journal:  Intern Emerg Med       Date:  2020-11-08       Impact factor: 3.397

4.  Diagnostic Delay of Pulmonary Embolism in COVID-19 Patients.

Authors:  Federica Melazzini; Margherita Reduzzi; Silvana Quaglini; Federica Fumoso; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Front Med (Lausanne)       Date:  2021-04-30

5.  Prognostic value of the lactate/albumin ratio for predicting mortality in patients with pneumosepsis in intensive care units.

Authors:  Murat Erdoğan; Hüseyin Avni Findikli
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

6.  Pulmonary thrombosis in 2019-nCoV pneumonia?

Authors:  Francesco Marongiu; Elvira Grandone; Doris Barcellona
Journal:  J Thromb Haemost       Date:  2020-04-15       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.